Collaboration and License Agreements - Narrative (Details)				1 Months Ended	3 Months Ended		12 Months Ended
	Dec. 26, 2020 USD ($)	Mar. 31, 2020 USD ($)	Mar. 30, 2020 USD ($)	Dec. 31, 2020 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) milestone	Jul. 31, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from collaborators	$ (146,400,000)				$ 0
Amounts due to Pfizer					39,244,000			$ 32,563,000
Deferred revenue					(25,141,000)	$ 70,491,000
Cost share advance from Pfizer					(25,831,000)	(18,285,000)
Imputed Interest					568,000
Accord license revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received					50,000,000	$ 0
Richter
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received		$ 40,000,000
Maximum payment from regulatory milestones achieved			$ 40,000,000
Regulatory milestone payments received			25,000,000
Maximum payment from sales-related milestones achieved			$ 107,500,000
Pfizer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum payment from regulatory milestones achieved	100,000,000									$ 100,000,000
Maximum payment from sales-related milestones achieved	$ 3,500,000,000
Percentage of revenue recognized	100.00%
Upfront payment received				$ 650,000,000
Maximum payment from milestones achieved	$ 3,800,000,000
Number of regulatory milestones | milestone									2
Maximum aggregate payment from milestones achieved	200,000,000
Costs covered by company									$ 100,000,000
Proceeds from collaborators	$ (150,000,000)
Repayment period	2 years
Reduction in cost share advance from implied financing costs	$ 3,600,000
Deferred revenue, recognition period	6 years
Amounts due to Pfizer					39,200,000			32,600,000
Amounts due to collaboration partner, share of profits					$ 18,000,000			$ 14,100,000
Percentage of revenue recognized by counterparty					50.00%			50.00%
Amounts due to collaboration partner, reimbursement of allowable expenses					$ 21,200,000			$ 18,500,000
Reimbursement of allowable expenses (as a percent)					50.00%			50.00%
Reimbursement of total expenses (as a percent)					100.00%
Cost share advance from Pfizer					$ (25,300,000)
Shared costs					25,800,000
Pfizer | R&D expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shared costs					8,500,000
Pfizer | SG&A expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shared costs					17,300,000
Pfizer | Forecast
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Costs covered by company							$ 50,000,000
Accord Healthcare, Ltd
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received					50,000,000
Accord Healthcare, Ltd | Accord license revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional milestone payments eligible to receive					$ 90,500,000